Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Streetwise Reports
$12.00
Provider: Streetwise Reports
$35.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

MusclePharm Corp Completes $12 Million Offering of Series D Convertible Stock


Tuesday, 5 Feb 2013 08:00am EST 

MusclePharm Corp announced that it has successfully completed the final closing of a $12.0 million registered direct offering of its Series D Convertible Preferred Stock. The Frost Group, LLC, headed by Miami entrepreneur Dr. Phillip Frost, was the lead investor in the offering and elected to increase its previously announced investment in the offering to a total of $2.9 million dollars. MusclePharm issued a total of 1,500,000 shares of its Series D Convertible Preferred Stock in a registered direct offering at a price of $8.00 per share. Each share of Series D Convertible Preferred Stock is convertible into two shares of common stock, subject to adjustment. The net proceeds to MusclePharm from the closings were approximately $10.8 million after deducting placement agent fees and offering expenses. GVC Capital LLC acted as the lead placement agent for this offering. 

Company Quote

12.95
0.2 +1.57%
3:56pm EDT